Advanced Search

Study Preview



Study Title and Description

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Author Nelson DR., Cooper JN., Lalezari JP., Lawitz E., Pockros PJ., Gitlin N., Freilich BF., Younes ZH., Harlan W., Ghalib R., Oguchi G., Thuluvath PJ., Ortiz-Lasanta G., Rabinovitz M., Bernstein D., Bennett M., Hawkins T., Ravendhran N., Sheikh AM., Varunok P., Kowdley KV., Hennicken D., McPhee F., Rana K., Hughes EA.
Country University of Florida, Gainesville, FL.
Year 2015
Numbers Pubmed ID: 25614962

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.